Lercanidipin Puren

Lercanidipine, the active ingredient in Lercanidipin Puren, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to treat hypertension in adult patients, helping to lower elevated blood pressure by relaxing vascular smooth muscle and improve overall cardiovascular risk profile. The drug provides a once‑daily dosing convenience.

GNH USA supplies Lercanidipin Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with quality compliance.

Lercanidipine is indicated for the management of hypertension, a condition characterized by chronically elevated arterial pressure. Hypertension: reduces systolic and diastolic blood pressure, helping to achieve target blood pressure levels and lower cardiovascular risk.

Lercanidipine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate headache often occurring early in therapy. - Flushing: transient warmth and redness of the face or neck. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness: sensation of light‑headedness, especially when standing. - Tachycardia: increased heart rate without other cardiac symptoms. - Palpitations: awareness of heartbeats, usually benign.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure leading to fainting. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of lips, tongue or airway requiring emergency care. - Hepatic enzyme elevation: significant increase in liver function tests. - Severe bradycardia: dangerously low heart rate. - Allergic reactions: rash, itching, or anaphylaxis.

When prescribing lercanidipine, clinicians should consider several safety measures to minimize risk. - Blood pressure monitoring: check baseline and periodic readings to assess efficacy. - Hepatic impairment: use caution and consider dose adjustment in patients with liver dysfunction. - Elderly patients: start at low dose and monitor for hypotension and dizziness. - Concomitant antihypertensives: avoid excessive blood pressure lowering when combined with other agents. - Severe aortic stenosis: contraindicated due to risk of precipitating hypotension. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, influencing its plasma levels or additive blood‑pressure effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase lercanidipine concentrations, raising toxicity risk. - Grapefruit juice: can markedly raise drug levels, leading to enhanced hypotensive effects. - Co‑administration with other calcium‑channel blockers: may cause excessive vasodilation and hypotension. - Nitrates: combined use can result in profound blood pressure fall. - Severe aortic stenosis: concurrent use with other vasodilators may precipitate cardiovascular collapse.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug efficacy. - Diuretics: may enhance antihypertensive effect, requiring dose adjustments. - Beta‑blockers: additive effect on heart rate and blood pressure. - NSAIDs: may attenuate antihypertensive response. - Digoxin: monitor for potential changes in plasma levels.